Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Slides:

Advertisements

Similar presentations

BAY , a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity Susann Santag, Franziska Siegel, Antje.

Advertisements

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Supplementary Figure S13

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

Effects of senescent cells on activity.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF).

Overexpression of HGF decreases MET protein levels.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Activity of MAC-321 (i. v. and p. o

Effect of MI-773 dosing on long-term efficacy.

Identification of Z-FA-FMK as a potent compound that increases SMN protein expression in HEK293 and patient fibroblast cells. Identification of Z-FA-FMK.

Senescence-associated inflammation, bone marrow suppression, and cardiac dysfunction. Senescence-associated inflammation, bone marrow suppression, and.

Therapy-induced senescence of primary cells.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

Liver AMPK is activated by oral administration of canagliflozin in mice, but this does not explain changes in RER. A: Phosphorylation of AMPK, ACC, and.

Effects of Z-FA-FMK on SMN protein expression in type II SMA patient fibroblast cells (GM22592). Effects of Z-FA-FMK on SMN protein expression in type.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

MTORC1 regulates basal GLUT4 protein expression independent of VWR exercise. mTORC1 regulates basal GLUT4 protein expression independent of VWR exercise.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

IL-6 production with increasing doses of endotoxin.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

PTENP1 sensitizes renal cancer cells to chemotherapy.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Quercetin induces arrest in G1 phase of cell cycle in P39 xenografts.

Quercetin induces apoptosis in P39 xenografts.

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

A, tumor growth studies in H1975 tumor–bearing mice.

Impairment of liver function upon treatment with 4D5MOCB-ETA.

CRA inhibits the growth of human tumor xenografts in vivo.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

BMX is a driver of castration resistance in vitro and in vivo.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Curative effect of W+T treatment in vivo.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

This Month in Gastroenterology

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. A, FGFR4 signaling was examined in Hep 3B tumors following twice-daily (bid) treatment with BLU9931 at indicated doses for a total of 4 doses. Hep 3B tumors were harvested at indicated times following the last dose. CYP7A1 mRNA levels were determined using qRT-PCR (3 mice/group) and are expressed relative to levels in tumors from vehicle-treated mice. The concentration of BLU9931 in plasma is expressed for each time point in ng/mL. B, In vivo antitumor efficacy of BLU9931 in Hep 3B tumors. BLU9931 was administered orally (po), twice daily at the indicated doses (9 mice/group). Sorafenib was administered orally once daily (qd) at 30 mg/kg (9 mice/group). Data are plotted as mean ± SEM. C, body weight was monitored during treatment with BLU9931 and sorafenib. Data are expressed as a percentage of body weight at the initiation of treatment and are plotted as mean ± SEM. Margit Hagel et al. Cancer Discovery 2015;5:424-437 ©2015 by American Association for Cancer Research